Navigating EU-UK Dual-Track Clinical Trial Regulation in Parallel

*Guest blog by Pivotal. For more information on the information in this blog post please contact Ms. Natalia Farr - [email protected]. If you would like to submit a guest blog please email [email protected].

Eva Font, Regulatory and Start-up Director – Pivotal

How sponsors can leverage both the EU Clinical Trials Regulation and UK’s reformed framework to achieve cost efficiencies, faster timelines, and stronger regulatory positioning.

EXECUTIVE SUMMARY

The post-Brexit regulatory landscape has created a unique — and frequently underutilized — opportunity for clinical trial sponsors. Rather than treating the European Union and United Kingdom as competing jurisdictions requiring a binary choice, forward-thinking sponsors are increasingly adopting a dual-track strategy: running a single, harmonized clinical project across both regulatory environments simultaneously.

This article examines how the EU Clinical Trials Regulation (EU CTR, Regulation No. 536/2014), now fully operational through CTIS, and the UK’s landmark Medicines for Human Use Clinical Trials Regulation 2025 (coming into force on 28 April 2026) create a framework that rewards sponsors who plan for both regions from the outset.

While submissions remain separate, the degree of procedural and substantive alignment is sufficient to enable meaningful cost savings, accelerated timelines, and a stronger overall regulatory position.

1. The Regulatory Landscape: A Window of Opportunity

The EU and UK now each have a modern, streamlined clinical trial framework and together they create a uniquely favourable environment for sponsors willing to plan across both regions.

In the EU, Regulation No. 536/2014 (EU CTR) ^[1]. has been fully in force since January 2025, replacing the patchwork of national requirements that previously made multi-country studies slow and costly. Through the Clinical Trials Information System (CTIS), sponsors can now submit a single application covering all participating EEA Member States, a significant simplification that rewards sponsors who know how to use it effectively.

In the UK, the Medicines for Human Use Clinical Trials Regulations 2025 ^[2] come into force on 28 April 2026, completing the most significant overhaul of UK clinical trial rules in two decades ^{[3] [4]}. The headline result for sponsors: significantly faster MHRA approval timelines, with a clear government target to reduce total trial set-up time to 150 days. Where a trial has already been authorized in the EU, a simplified notification pathway may apply, meaning sponsors who move in Europe first can move even faster in the UK.

The practical upshot is that EU and UK submissions, while legally independent, can be run in parallel with a high degree of shared infrastructure and sponsors who understand this are gaining a meaningful competitive advantage over those who treat the two regions as alternatives.

2. Obtaining Efficiencies: The EU-UK Dual-Track Advantage

A common misconception is that running EU and UK trials simultaneously doubles costs. In practice, a well-designed dual-track strategy shares a substantial proportion of the operational infrastructure, meaning the marginal cost of the second jurisdiction is far lower than establishing a clinical trial from scratch. The savings accumulate across four key areas.

2.1 Single Protocol with Regional Addenda: One Medical and CMC Writing Effort

Both EU CTR 536/2014 and the UK’s amended regulations are grounded in ICH GCP (E6 R3) and share a broadly aligned clinical documentation framework. A single, ICH-compliant protocol can serve as the core document for both submissions.

This approach yields direct savings across:

Clinical Protocol: one core document.
Investigator’s Brochure (IB): a single core IB with shared Reference Safety Information (RSI) section aligned to the EU CTR ^[5].
IMPD: a unified IMPD covers both geographies; defining QP release for both regions.

2.2 Combined Site Start-Up (SSU) Workstreams: Parallel Execution

While the CTIS submission (EU) and the IRAS/Combined Review submission (UK) are legally separate processes with independent timelines, there is no regulatory barrier to preparing and executing them in parallel. A well-resourced SSU team can:

Draft and finalize the core CTA dossier in a format adaptable to both CTIS modules and the UK IRAS system
Run country/site feasibility, selection, and contracting activities concurrently for EU and UK sites
Conduct investigator and coordinator training using shared materials, with jurisdiction-specific modules appended
Negotiate Clinical Trial Agreements using study regional budgets adjusted per country

The MHRA’s accelerated timelines mean that UK approvals frequently complete while EU Member State review processes are still ongoing. Sponsors who commence UK SSU activities in parallel, rather than sequentially after EU approval, can achieve First Patient In (FPI) acceleration of several weeks to months ^[6].

2.3 Leveraging Overlapping Standard of Care

The EU and UK share broadly equivalent clinical practice standards, underpinned by common ICH guidelines, EMA/MHRA scientific guidance, and NHS/NICE frameworks that largely track CHMP recommendations. Background therapies, concomitant medications, eligibility criteria, and disease classification systems are directly transferable or require only minor adaptation. Where divergences exist, for example, differing authorized indications for a comparator, these are addressed through IMPD and quality documentation, not through parallel study design.

2.4 Central Safety, Pharmacovigilance, Medical Monitoring, and Biostatistics

The single most significant cost saving lies in avoiding duplication of central oversight functions. The regulatory alignment between EU CTR 536/2014 and the UK 2025 Regulations on DSUR structure, SUSAR reporting thresholds, and safety report timelines is sufficiently close that sponsors can operate a single global safety, pharmacovigilance, medical monitoring, and biostatistics function with jurisdiction-specific submission modules, avoiding the cost of separate teams for each region.

3. Strategic Advantages of Running Both EU and UK

Beyond cost efficiency, running a dual EU+UK program delivers strategic advantages that compound over the lifecycle of the development program and have a material impact on regulatory positioning, commercial outlook, and investor perception.

3.1 Faster Startup and First Patient In: With MHRA Leading the Way

The MHRA’s risk-proportionate approval system represents one of the fastest major regulatory review timelines in the world. Under the 2025 regulations’ notification scheme, trials already authorized in the EU (or USA) may be notified to the MHRA rather than requiring full approval, potentially reducing UK entry requirements even further. Beyond regulatory approval, the UK Government has set an ambitious target to reduce total clinical trial set-up time (from application to first participant) from approximately 250 days to 150 days. The HRA, working as part of the UK Clinical Research Delivery (UKCRD) programme alongside NIHR and NHS England, is driving this through streamlined Combined Review (now embedded in law), standardized NHS contracting via the National Contract Value Review, and digital infrastructure modernization. The HRA has committed to completing 100% of clinical trial approvals within a maximum of 60 days, with a median below 40 days, to support this target ^[7].

For sponsors, this creates a genuine ‘fast-entry’ mechanism: UK sites can open and begin screening while EU CTIS Part II national reviews are still underway. By the time EU sites are ready to open, UK sites may already be enrolling, generating safety and operational data that benefits the entire trial.

3.2 Stronger Regulatory Position for Future Marketing Plans

A development program with robust data from both EU and UK jurisdictions is materially stronger at the point of marketing authorization application than one anchored in only a single geography. EMA scientific committees and the MHRA each weigh on the quality of the clinical evidence base; a dataset reflecting site diversity, patient population breadth, and dual-regulatory oversight signals, a program that has been stress-tested across complementary but distinct environments.

3.3 Patient Population Diversity and Site Resilience

Through CTIS, sponsors can select individual Member States for their trial, with each country retaining its own Part II national assessment covering ethics, site suitability, and local requirements. This means access to a combined EEA population exceeding 450 million people is built incrementally, country by country, but the streamlined CTIS process (with a single Part I scientific assessment valid across all selected states) makes multi-country expansion significantly more efficient than under the previous directive. This scale is invaluable for rare disease recruitment, subgroup enrichment in precision medicine programs, and geographic spread that supports broad labelling claims. The UK, with a population of approximately 67 million, offers a complementary set of advantages: a deeply integrated national health system enabling efficient data linkage, strong academic-led investigator networks, and NHS-embedded patient identification pipelines.

The two populations are distinct enough to contribute meaningfully to data diversity, yet similar enough to permit pooled primary endpoint analyses, particularly valuable in oncology, rare diseases, immunology, and neurology. Distributing enrolment across both jurisdictions also introduces natural resilience: regulatory or logistical disruption in one region does not halt the entire program, as sites under independent authorization continue enrolling while issues elsewhere are resolved.

3.4 Increased Credibility with Investors and Partners

For sponsors engaged in partnering discussions, licensing negotiations, or equity financing, a clinical program spanning both EU and UK regulatory environments sends a clear signal of regulatory ambition and operational sophistication. A dual EU+UK program also simplifies the due diligence process: the existence of two independent regulatory authorizations provides transaction counterparties with greater confidence in the program’s robustness than a single-jurisdiction authorization can.

4. What Sponsors Miss with a Single-Region Strategy

The opportunity cost of limiting a development program to a single jurisdiction is substantial — regardless of which region the sponsor chooses.

4.1 The Cost of a UK-Only Strategy

A UK-only strategy is limiting in ways that compound over time. The EU does not automatically recognize UK trial data, and the EU’s population scale (450+ million) is irreplaceable for large-sample programs in oncology, rare diseases, and precision medicine. Access to EU investigators, academic centers, and the multi-country site network available through CTIS simply cannot be replicated by a single-country program.

4.2 The Cost of an EU-Only Strategy

Conversely, an EU-only strategy forfeits significant advantages. The MHRA’s pragmatic, science-led approach and its track record of early authorization for ATMPs and cell and gene therapies via pathways such as ILAP offer a route to market that has no direct EU equivalent. The NHS research ecosystem — through the NIHR Clinical Research Network — consistently delivers among the highest enrollment rates per site globally. Excluding the UK narrows regulatory leverage, investor credibility, and patient access precisely when breadth of evidence matters most.

Both choices share a common consequence: a narrower data package at the point of marketing authorization, a more concentrated commercial footprint, and a less compelling story for investors evaluating the program’s global potential.

5. How Pivotal Can Help

Executing a dual EU+UK strategy requires an operational partner with established teams and genuine experience in both jurisdictions. Pivotal, a full-service European CRO headquartered in Madrid with over 25 years of experience, has been providing exactly that since 2001. Pivotal’s regulatory teams work within both the EU CTR and UK frameworks daily, managing EU authorization within CTIS since the regulation came into force, with validation achieved on every application and all RFI deadlines met.

Pivotal runs EU and UK submission workstreams concurrently with shared tools, harmonized processes, and a single point of accountability. For UK-specific delivery, a dedicated in-country team covers medical monitoring, project management, CRA activities, and regulatory submissions including IRAS, MHRA/HRA Combined Review, NIHR portfolio entry, and NHS contracting. Regulatory strategy, safety oversight, and operations decisions are led by senior professionals throughout the project lifecycle, supported by a positive track record through European competent authority inspections.

6. Conclusions

The EU CTR (No. 536/2014) and the UK’s 2025 Clinical Trials Regulations together define a dual-track environment in which a single, well-designed program can access the regulatory strengths of both jurisdictions. Sponsors who plan for EU and UK from protocol design stage, sharing documentation, safety oversight, and site start-up activities achieve the cost efficiency of a single-region program while capturing the strategic and commercial advantages of both.

6.1 Seven Steps to Get Started

On that basis, we offer the following practical recommendations for sponsors evaluating a dual EU+UK development strategy:

Design the protocol for dual submission from Day 1: Engage regulatory affairs specialists with dual EU/UK expertise at protocol concept stage.
Align the IB and RSI update schedule with both jurisdictions: A single annual RSI update cycle, timed to precede the DSUR data lock point, satisfies both jurisdictions.
Submit CTIS and IRAS applications in parallel: Submit for IRAS/Combined Review as soon as the CTIS submission is filed.
Leverage the MHRA notification scheme where applicable: If your program has already obtained EU/US authorization, assess eligibility for the MHRA notification pathway.
Negotiate unified vendor contracts with EU+UK scope: Specify the combined patient population in all RFP documents to secure volume pricing.
Establish a single Central Safety function: Invest in a unified safety database and pharmacovigilance team from the outset.
Consider UK site activation as an enrollment buffer: Plan UK sites to begin screening 4–6 weeks ahead of EU sites where MHRA timelines permit.

In an era of increasing global competition for clinical trial sites, patients, and investment, the dual EU+UK model is not merely an option worth considering. it is fast becoming the standard of strategic planning for development programs with serious commercial ambitions in either or both markets.

References